The National Agency for the Safety of Medicines and Health Products (ANSM) has launched a pharmacoepidemiology study consisting of comparing the state of health of patients who took the new formula of Levothyrox in France in 2017 to that of people treated with the old Levothyrox formula the previous year. The conclusions of this study, which involved more than 2 million patients, have just been presented.
No increase in work stoppages or hospitalizations
These results “do not provide an argument in favor of an increased risk of serious health problems during the months following the initiation of the new formula of Levothyrox” underlines the ANSM. “Indeed, they do not highlight any specific increase in the occurrence of hospitalizations, of deceased, work stoppages of at least 7 days, or consumption of drugs used to treat somatic symptoms such as those declared in pharmacovigilance during the transition to the new formula of Levothyrox.
On the other hand, the study highlights a 2% increase in medical consultations and an increase in the use of anxiolytic drugs. At the same time, the frequency of TSH assays increased significantly (+31%) following the switch to the new formula.
Read also :
Levothyrox: 1 million patients abandoned the drug
Thyroid disorders: what drugs are available?
